PT - JOURNAL ARTICLE AU - Halfon, Philippe AU - Penaranda, Guillaume AU - Khiri, Hacène AU - Garcia, Vincent AU - Drouet, Hortense AU - Philibert, Patrick AU - Psomas, Christina AU - Delord, Marion AU - Allemand-Sourrieu, Julie AU - Retornaz, Frédérique AU - Charpin, Caroline AU - Gonzales, Thomas AU - Pegliasco, Hervé AU - Allardet-Servent, Jérôme TI - An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients AID - 10.1101/2021.01.13.21249254 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.13.21249254 4099 - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249254.short 4100 - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249254.full AB - Background Diagnosing SARS CoV-2 infection with certainty is essential for appropriate case management. We investigated the combination of rapid antigen detection (RAD) and RT-qPCR assays in a stepwise procedure to optimize the detection of COVID-19.Methods From August 2020 to November 2020, 43,399 patients were screened in our laboratory for COVID-19 diagnostic by RT-qPCR using nasopharyngeal swab. Overall, 4,691 of the 43,399 were found to be positive, and 200 were retrieved for RAD testing allowing comparison of diagnostic accuracy between RAD and RT-qPCR. Cycle threshold (Ct) and time from symptoms onset (TSO) were included as covariates.Results The overall sensitivity, specificity, PPV, NPV, LR-, and LR+ of RAD compared with RT- qPCR were 72% (95%CI 62%–81%), 99% (95% CI95%–100%), 99% (95%CI 93%–100%), and 78% (95%CI 70%–85%), 0.28 (95%CI 0.21-0.39), and 72 (95%CI 10-208) respectively. Sensitivity was higher for patients with Ct ≤ 25 regardless of TSO: TSO ≤ 4 days 92% (95%CI 75%–99%), TSO > 4 days 100% (95%CI 54%–100%), and asymptomatic 100% (95%CI 78-100%). Overall, combining RAD and RT-qPCR would allow reducing from only 4% the number of RT-qPCR needed.Conclusion This study highlights the risk of misdiagnosing COVID-19 in 28% of patients if RAD is used alone. Thus, negative results from RAD needs to be confirmed by RT-qPCR prior to making treatment decisions. A stepwise analysis that combines RAD and RT-qPCR would be an efficient screening procedure for COVID-19 detection and may facilitate the control of the outbreak.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.health-data-hub.fr Funding StatementThere was no funding source for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Protection des Personnes (CPP) Sud-Mediterranee II - Hopital Sainte Marguerite - Pavillon 9, Marseille, FRANCE (http://www.cpp-sudmed2.fr/) Decision: exemption of approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available immediately after publication with no end date to researchers who provide a methodologically sound proposal. Requests should be addressed by email to g.penaranda@alphabio.fr.